Solid Biosciences (SLDB) Stock Forecast & Price Target

Compare

1,428 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SLDB Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Solid

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SLDB Stock 12 Month Forecast

Average Price Target

$16.00

▲(238.98%Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $16.00 with a high forecast of $20.00 and a low forecast of $10.00. The average price target represents a 238.98% change from the last price of $4.72.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","21":"$21","6.75":"$6.75","11.5":"$11.5","16.25":"$16.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.75,11.5,16.25,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.54,4.806153846153846,6.072307692307692,7.338461538461539,8.604615384615386,9.87076923076923,11.136923076923077,12.403076923076924,13.669230769230769,14.935384615384617,16.201538461538462,17.467692307692307,18.733846153846155,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.54,4.498461538461538,5.456923076923077,6.415384615384616,7.373846153846154,8.332307692307692,9.290769230769232,10.24923076923077,11.207692307692309,12.166153846153847,13.124615384615385,14.083076923076923,15.041538461538462,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.54,4.036923076923077,4.533846153846154,5.030769230769231,5.527692307692307,6.024615384615385,6.521538461538461,7.018461538461539,7.515384615384615,8.012307692307692,8.509230769230768,9.006153846153847,9.503076923076922,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.54,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.27,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.78,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.75,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.79,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$16.00

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yigal NochomovitzCiti

Citi

$14

Buy

196.61%

Upside

Initiated

06/26/25

Solid Biosciences: Promising DMD Gene Therapy with Favorable Risk/Reward Profile Earns Buy Rating

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Solid Biosciences (NASDAQ: SLDB) and Novo Nordisk (NYSE: NVO)

Biren AminPiper Sandler

Piper Sandler

$17

Buy

260.17%

Upside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: Cytek Biosciences (NASDAQ: CTKB), Dexcom (NASDAQ: DXCM) and Solid Biosciences (NASDAQ: SLDB)

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

$16

Buy

238.98%

Upside

Reiterated

06/17/25

Solid Biosciences (SLDB) Gets a Buy from Cantor Fitzgerald

Arthur He CFAH.C. Wainwright

H.C. Wainwright

$20

Buy

323.73%

Upside

Reiterated

06/17/25

Solid Biosciences' SGT-003 Gains Favor Amid Competitor Setbacks, Justifying Buy Rating

Joseph SchwartzLeerink Partners

Leerink Partners

$20

Buy

323.73%

Upside

Reiterated

06/16/25

Solid Biosciences' Innovative Gene Therapy for DMD Earns Buy Rating from Analyst Joseph Schwartz

Anupam RamaJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/21/25

Solid Biosciences: Undervalued Gem with Promising Gene Therapy Pipeline and Upcoming Catalysts

Maury RaycroftJefferies

Jefferies

$16→$15

Buy

217.80%

Upside

Reiterated

05/16/25

Solid Biosciences (SLDB) PT Lowered to $15 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Solid Biosciences (NASDAQ: SLDB) to $15.00 (from $16.00) while maintaining a Buy rating.

Laura ChicoWedbush

Wedbush

$17

Buy

260.17%

Upside

Reiterated

05/16/25

Wedbush Sticks to Its Buy Rating for Solid Biosciences (SLDB)

Gena WangBarclays

Barclays

$15→$10

Buy

111.86%

Upside

Reiterated

05/16/25

Barclays Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/16/25

Solid Biosciences: Promising Developments and Potential Growth in Duchenne Muscular Dystrophy Treatment

Silvan TuerkcanCitizens JMP

Citizens JMP

$15

Buy

217.80%

Upside

Reiterated

05/16/25

Solid Biosciences (SLDB) Gets a Buy from Citizens JMP

Geulah LivshitsChardan Capital

Chardan Capital

$16

Buy

238.98%

Upside

Reiterated

03/07/25

Solid Biosciences (SLDB) Gets a Buy from Chardan CapitalUpdating our model for 4Q24 and FY24 financials leaves our PT at $16.

David HoangDeutsche Bank

Deutsche Bank

$16

Buy

238.98%

Upside

Reiterated

07/17/24

Solid Biosciences' SGT-003: A Promising Leap in DMD Therapy with Cardiac Safety Superiority

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yigal NochomovitzCiti

Citi

$14

Buy

196.61%

Upside

Initiated

06/26/25

Solid Biosciences: Promising DMD Gene Therapy with Favorable Risk/Reward Profile Earns Buy Rating

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Solid Biosciences (NASDAQ: SLDB) and Novo Nordisk (NYSE: NVO)

Biren AminPiper Sandler

Piper Sandler

$17

Buy

260.17%

Upside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: Cytek Biosciences (NASDAQ: CTKB), Dexcom (NASDAQ: DXCM) and Solid Biosciences (NASDAQ: SLDB)

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

$16

Buy

238.98%

Upside

Reiterated

06/17/25

Solid Biosciences (SLDB) Gets a Buy from Cantor Fitzgerald

Arthur He CFAH.C. Wainwright

H.C. Wainwright

$20

Buy

323.73%

Upside

Reiterated

06/17/25

Solid Biosciences' SGT-003 Gains Favor Amid Competitor Setbacks, Justifying Buy Rating

Joseph SchwartzLeerink Partners

Leerink Partners

$20

Buy

323.73%

Upside

Reiterated

06/16/25

Solid Biosciences' Innovative Gene Therapy for DMD Earns Buy Rating from Analyst Joseph Schwartz

Anupam RamaJ.P. Morgan

J.P. Morgan

―

Buy

―

Reiterated

05/21/25

Solid Biosciences: Undervalued Gem with Promising Gene Therapy Pipeline and Upcoming Catalysts

Maury RaycroftJefferies

Jefferies

$16→$15

Buy

217.80%

Upside

Reiterated

05/16/25

Laura ChicoWedbush

Wedbush

$17

Buy

260.17%

Upside

Reiterated

05/16/25

Wedbush Sticks to Its Buy Rating for Solid Biosciences (SLDB)

Gena WangBarclays

Barclays

$15→$10

Buy

111.86%

Upside

Reiterated

05/16/25

Barclays Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

05/16/25

Solid Biosciences: Promising Developments and Potential Growth in Duchenne Muscular Dystrophy Treatment

Silvan TuerkcanCitizens JMP

Citizens JMP

$15

Buy

217.80%

Upside

Reiterated

05/16/25

Solid Biosciences (SLDB) Gets a Buy from Citizens JMP

Geulah LivshitsChardan Capital

Chardan Capital

$16

Buy

238.98%

Upside

Reiterated

03/07/25

Solid Biosciences (SLDB) Gets a Buy from Chardan CapitalUpdating our model for 4Q24 and FY24 financials leaves our PT at $16.

David HoangDeutsche Bank

Deutsche Bank

$16

Buy

238.98%

Upside

Reiterated

07/17/24

Solid Biosciences' SGT-003: A Promising Leap in DMD Therapy with Cardiac Safety Superiority

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Solid Biosciences

1 Month

xxx

Success Rate

3/10 ratings generated profit

Average Return

-2.61%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 30.00% of your transactions generating a profit, with an average return of -2.61% per trade.

3 Months

xxx

Success Rate

5/10 ratings generated profit

Average Return

+7.23%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +7.23% per trade.

1 Year

Sami CorwinWilliam Blair

Success Rate

3/6 ratings generated profit

Average Return

+12.48%

reiterated a buy rating 2 months ago

Copying Sami Corwin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +12.48% per trade.

2 Years

xxx

Success Rate

3/6 ratings generated profit

Average Return

+12.48%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +12.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SLDB Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SLDB has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SLDB average Analyst price target in the past 3 months is 16.00.

Each month's total comprises the sum of three months' worth of ratings.

SLDB Financial Forecast

SLDB Earnings Forecast

Next quarter’s earnings estimate for SLDB is -$0.50 with a range of -$0.59 to -$0.42. The previous quarter’s EPS was -$0.59. SLDB beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.35% of the time in the same period. In the last calendar year SLDB has Outperformed its overall industry.

SLDB Sales Forecast

Next quarter’s sales forecast for SLDB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SLDB beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.77% of the time in the same period. In the last calendar year SLDB has Preformed in-line its overall industry.

SLDB Stock Forecast FAQ

What is SLDB’s average 12-month price target, according to analysts?

Based on analyst ratings, Solid Biosciences’s 12-month average price target is 16.00.

What is SLDB’s upside potential, based on the analysts’ average price target?

Solid Biosciences has 238.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SLDB a Buy, Sell or Hold?

Solid Biosciences has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is Solid Biosciences’s price target?

The average price target for Solid Biosciences is 16.00. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 238.98% Increase from the current price of $4.72.

What do analysts say about Solid Biosciences?

Solid Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of SLDB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Solid Biosciences (SLDB) Stock Forecast & Price Target

SLDB Analyst Ratings

SLDB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Solid Biosciences

SLDB Analyst Recommendation Trends

SLDB Financial Forecast

SLDB Earnings Forecast

SLDB Sales Forecast

SLDB Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts